Journal article

Multidrug-resistant genotype (ABCB1) and seizure recurrence in newly treated epilepsy: Data from international pharmacogenetic cohorts

Cassandra Szoeke, Graeme J Sills, Patrick Kwan, Slave Petrovski, Mark Newton, Nikolas Hitiris, Larry Baum, Samuel F Berkovic, Martin J Brodie, Leslie J Sheffield, Terence J O'Brien

EPILEPSIA | WILEY | Published : 2009


PURPOSE: The association between a specific polymorphism (3435C>T) in the ABCB1 gene, coding for the membrane drug transporter P-glycoprotein (PgP), and pharmacoresistance to seizure control is controversial. Studies have been limited by multiple drug use, chronic cohorts with varying definitions, and retrospective clinical data. Herein we examine the relationship of this polymorphism with seizure recurrence in three independent international cohorts of patients newly treated for epilepsy. METHODS: Data were collected on demographics, medication details, and seizure control after 12  months of treatment. The distribution of ABCB1 3435C>T genotypes was compared between patients with and witho..

View full abstract


Awarded by Research Grants Council of the Hong Kong Special Administrative Region, China

Funding Acknowledgements

The study was supported in the past by a Pfizer Neuroscience Grant (C.S.) and a grant from the Victor Hurley Foundation of Melbourne Health (C.S.). A Bio21 Fellowship (C.S.), University of Melbourne fostered the international collaboration. The work was also partly supported by a grant from the Research Grants Council of the Hong Kong Special Administrative Region, China (Project no. CUHK4466/06M) (P.K., L.B., T.J.O.). BioGrid Australia was responsible for database management. Dr. Nick Lawn enrolled the patients from the Royal Perth Hospital, Western Australia.We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.Disclosure: C.S. has received a Pfizer Neuroscience Grant. T.J.O. has received financial support for his research from the NH&MRC (Australia), NARSAD (U.S.A.), DEST (Australia), The Royal Melbourne Hospital Neuroscience Foundation, The Victorian Neurotrauma Initiative, and research and educational grants from the Pharmaceutical Industry (Pfizer, UCB, Jansen-Cilag, GSK, Abbott, Sanofi-Aventis). In addition he is on a Medical Advisory Board for Jansen-Cilag (Australia) and Pfizer (Australia), work for which he has received Honoraria. L.J.S. has received financial support from the Murdoch Childrens Research Institute for this research. He is a director of a pharmacogenetic testing company, which does not do genetic testing for ABCB1. Other authors report no conflict of interest.